Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model

10 Aug 2017

Abstract excerpt

No treatments exist to slow or halt Parkinson's disease (PD) progression; however, inhibition of leucine-rich repeat kinase 2 (LRRK2) activity represents one of the most promising therapeutic strategies. Genetic ablation and pharmacological LRRK2 inhibition have demonstrated promise in blocking α-synuclein (α-syn) pathology. However, LRRK2 kinase inhibitors may reduce LRRK2 activity in several tissues and induce...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to biodegradable polymer synthesis and properties
Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28918051
DOI: 10.1016/j.omtn.2017.08.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse ModelPMID 28918051Read ↗

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s diseaseSemantic proximity Read ↗

Antisense oligonucleotides targeting alpha-synuclein reduce pre-formed fibril-induced Lewy pathology and improve some domains of cognitive and motor performanceSemantic proximity Read ↗

LRRK2 modifies α-syn pathology and spread in mouse models and human neuronsSemantic proximity Read ↗

Alpha-synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s diseaseSemantic proximity Read ↗

The therapeutic potential of LRRK2 and alpha-synuclein in Parkinson's disease.Semantic proximity Read ↗

Neuron-autonomous susceptibility to induced synuclein aggregation is exacerbated by endogenous Lrrk2 mutations and ameliorated by Lrrk2 genetic knock-outSemantic proximity Read ↗

Long-term exposure to PFE-360 in the AAV-α-synuclein rat model: findings and implicationsSemantic proximity Read ↗

Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.Semantic proximity Read ↗

G2019S LRRK2 mutation facilitates α-synuclein neuropathology in aged mice.Semantic proximity Read ↗

Aberrant adenosine A2A receptor signaling contributes to neurodegeneration and cognitive impairments in a mouse model of synucleinopathy.Semantic proximity Read ↗

G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons.Semantic proximity Read ↗

Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic MiceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.